WITHDRAWN: Nasal decongestants for the common cold

Area of Science:

• Pharmacology
• Clinical Trials
• Respiratory Medicine

Background:

• The common cold is a frequent cause of illness, with nasal congestion being a primary symptom.
• Numerous therapies exist for cold symptom relief, yet robust evidence for nasal decongestants is lacking.
• A meta-analysis of controlled clinical trials on nasal decongestants for the common cold was previously unavailable.

Purpose of the Study:

• To evaluate the effectiveness of nasal decongestants in alleviating nasal congestion in adults and children with the common cold.
• To identify potential adverse effects associated with nasal decongestant use.
• To provide evidence-based recommendations for the use of nasal decongestants in common cold management.

Main Methods:

• A systematic review and meta-analysis of randomized, placebo-controlled trials of single-active oral and topical nasal decongestants.
• Searches conducted across major databases including CENTRAL, MEDLINE, OLDMEDLINE, and EMBASE up to September 2006.
• Data extraction by two independent reviewers, with calculation of weighted mean difference (WMD) for subjective outcomes and standardized mean difference (SMD) for objective outcomes.

Main Results:

• Seven studies in adults met inclusion criteria; no studies in children were identified.
• A single oral dose of nasal decongestant showed a modest 6% decrease in subjective congestion symptoms compared to placebo.
• Repeated doses over 3-5 days yielded a small 4% benefit, with reduced nasal airway resistance observed in both cases. Insomnia was a minor adverse event associated with pseudoephedrine.

Conclusions:

• Nasal decongestants provide modest, short-term relief for adult common cold congestion, with some benefit from regular use.
• Adverse events in adults are generally rare and mild.
• Insufficient data exists for pediatric use; nasal decongestants are not recommended for children under 12 with the common cold.